Cannabinoid type 1 receptor blockade induces transdifferentiation towards a brown fat phenotype in white adipocytes

Diabetes, Obesity and Metabolism

Volumn 12, Issue 2, 2010, Pages 158-166

  Perwitz, N ^a   Wenzel, J ^a   Wagner, I ^a   Buning J ^a   Drenckhan, M ^a   Zarse, K ^b   Ristow, M ^b   Lilienthal, W ^c   Lehnert, H ^a   Klein, J ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^c SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

Adipocyte; Endocannabinoid action; Mitochondrial biogenesis; Oxygen consumption; Transdifferentiation; Uncoupling protein 1

Indexed keywords

CYTOCHROME C OXIDASE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; RIMONABANT; SMALL INTERFERING RNA; UNCOUPLING PROTEIN 1;

ANIMAL CELL; ARTICLE; BROWN ADIPOSE TISSUE; CELL STIMULATION; CELL TRANSDIFFERENTIATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GLUCOSE HOMEOSTASIS; INSULIN SENSITIVITY; MITOCHONDRION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OXYGEN CONSUMPTION; PROTEIN EXPRESSION; THERMOGENESIS; WEIGHT REDUCTION; WHITE ADIPOSE TISSUE;

EID: 73349119690     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2009.01133.x     Document Type: Article

References (34)

1. Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 1998, 92:829-839.
2. Medina-Gomez G, Gray S, Vidal-Puig A. Adipogenesis and lipotoxicity: role of peroxisome proliferator-activated receptor gamma (PPARgamma) and PPARgammacoactivator-1 (PGC1). Public Health Nutr 2007, 10:1132-1137.
3. Tiraby C, Tavernier G, Lefort C. Acquirement of brown fat cell features by human white adipocytes. J Biol Chem 2003, 278:33370-33376.
4. Pagotto U, Vicennati V, Pasquali R. The endocannabinoid system and the treatment of obesity. Ann Med 2005, 37:270-275.
5. Perwitz N, Fasshauer M, Klein J. Cannabinoid receptor signaling directly inhibits thermogenesis and alters expression of adiponectin and visfatin. Horm Metab Res 2006, 38:356-358.
6. Cota D, Marsicano G, Tschop M. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003, 112:423-431.
7. Ravinet Trillou C, Delgorge C, Menet C, Arnone M, Soubrie P. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 2004, 28:640-648.
8. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005, 365:1389-1397.
9. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005, 353:2121-2134.
10. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006, 295:761-775.
11. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006, 368:1660-1672.
12. Fasshauer M, Klein J, Kriauciunas KM, Ueki K, Benito M, Kahn CR. Essential role of insulin receptor substrate 1 in differentiation of brown adipocytes. Mol Cell Biol 2001, 21:319-329.
13. Klein J, Fasshauer M, Klein HH, Benito M, Kahn CR. Novel adipocyte lines from brown fat: a model system for the study of differentiation, energy metabolism, and insulin action. Bioessays 2002, 24:382-388.
14. Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 2002, 30:e36.
15. Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005, 8:585-589.
16. Pagano C, Pilon C, Calcagno A. The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms. J Clin Endocrinol Metab 2007, 92:4810-4819.
17. Roche R, Hoareau L, Bes-Houtmann S. Presence of the cannabinoid receptors, CB1 and CB2, in human omental and subcutaneous adipocytes. Histochem Cell Biol 2006, 126:177-187.
18. Spoto B, Fezza F, Parlongo G. Human adipose tissue binds and metabolizes the endocannabinoids anandamide and 2-arachidonoylglycerol. Biochimie 2006, 88:1889-1897.
19. Howlett AC. Inhibition of neuroblastoma adenylate cyclase by cannabinoid and nantradol compounds. Life Sci 1984, 35:1803-1810.
20. Bayewitch M, Avidor-Reiss T, Levy R, Barg J, Mechoulam R, Vogel Z. The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling. FEBS Lett 1995, 375:143-147.
21. Felder CC, Joyce KE, Briley EM. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 1995, 48:443-450.
22. Pacheco MA, Ward SJ, Childers SR. Identification of cannabinoid receptors in cultures of rat cerebellar granule cells. Brain Res 1993, 603:102-110.
23. Bellocchio L, Cervino C, Vicennati V, Pasquali R, Pagotto U. Cannabinoid type 1 receptor: another arrow in the adipocytes' bow. J Neuroendocrinol 2008, 20(Suppl. 1):130-138.
24. Gary-Bobo M, Elachouri G, Scatton B, Le Fur G, Oury-Donat F, Bensaid M. The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes. Mol Pharmacol 2006, 69:471-478.
25. Nicholls DG, Rial E. A history of the first uncoupling protein, UCP1. J Bioenerg Biomembr 1999, 31:399-406.
26. Wilson-Fritch L, Burkart A, Bell G. Mitochondrial biogenesis and remodeling during adipogenesis and in response to the insulin sensitizer rosiglitazone. Mol Cell Biol 2003, 23:1085-1094.
27. Herling AW, Kilp S, Elvert R, Haschke G, Kramer W. Increased energy expenditure contributes more to the body weight-reducing effect of rimonabant than reduced food intake in candy-fed wistar rats. Endocrinology 2008, 149:2557-2566.
28. Verty AN, Allen AM, Oldfield BJ. Obesity (Silver Spring) 2009, 17:254-261. The effects of rimonabant on brown adipose tissue in rat: implications for energy expenditure.
29. Jbilo O, Ravinet-Trillou C, Arnone M. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J 2005, 19:1567-1569.
30. Tedesco L, Valerio A, Cervino C. Cannabinoid type 1 receptor blockade promotes mitochondrial biogenesis through endothelial nitric oxide synthase expression in white adipocytes. Diabetes 2008, 57:2028-2036.
31. Towler MC, Hardie DG. AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 2007, 100:328-341.
32. Liu YL, Connoley IP, Wilson CA, Stock MJ. Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int J Obes (Lond) 2005, 29:183-187.
33. Motaghedi R, McGraw TE. The CB1 endocannabinoid system modulates adipocyte insulin sensitivity. Obesity (Silver Spring) 2008, 16:1727-1734.
34. Esposito I, Proto MC, Gazzerro P. The cannabinoid CB1 receptor antagonist rimonabant stimulates 2-deoxyglucose uptake in skeletal muscle cells by regulating the expression of phosphatidylinositol-3-kinase. Mol Pharmacol 2008, 74:1678-1686.